Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug Applications for Combination Drug Medicated Feeds Containing an Arsenical Drug; Correction, 18990 [2014-07702]
Download as PDF
<![CDATA[
18990
Federal Register / Vol. 79, No. 66 / Monday, April 7, 2014 / Rules and Regulations
(L) Fokker Drawing W69240, Sheet 004,
Issue B, dated November 12, 2009.
(M) Fokker Drawing W69335, Sheet 001,
dated November 12, 2009.
(N) Fokker Drawing W69405, Sheet 001,
dated November 12, 2009.
(O) Fokker Drawing W69710, Sheet 004,
Issue B, dated November 12, 2008.
(ii) Reserved.
(3) For service information identified in
this AD, contact Fokker Services B.V.,
Technical Services Dept., P.O. Box 1357,
2130 EL Hoofddorp, the Netherlands;
telephone +31 (0)88–6280–350; fax +31
(0)88–6280–111; email
technicalservices@fokker.com; Internet
https://www.myfokkerfleet.com.
(4) You may view this service information
at the FAA, Transport Airplane Directorate,
1601 Lind Avenue SW., Renton, WA. For
information on the availability of this
material at the FAA, call 425–227–1221.
(5) You may view this service information
that is incorporated by reference at the
National Archives and Records
Administration (NARA). For information on
the availability of this material at NARA, call
202–741–6030, or go to: https://
www.archives.gov/federal-register/cfr/ibrlocations.html.
Issued in Renton, Washington, on March
27, 2014.
Jeffrey E. Duven,
Manager, Transport Airplane Directorate,
Aircraft Certification Service.
[FR Doc. 2014–07326 Filed 4–4–14; 8:45 am]
Medicine (HFV–6), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9019,
George.haibel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In FR Doc.
2014–02616, appearing on page 10974
in the Federal Register of February 27,
2014, the following corrections are
made:
On page 10974, in the third column,
in the 2d line of the ‘‘SUMMARY’’
section remove ‘‘69’’ and add in its
place ‘‘68’’.
On page 10975, the first bulleted text
‘‘Huvepharma AD, 5th Floor, 3A
Nikolay Haitov Str., 1113 Sofia, Bulgaria
has requested that FDA withdraw
approval of the following 16 NADAs
and 8 ANADAs’’ is corrected to read
‘‘Huvepharma AD, 5th Floor, 3A
Nikolay Haitov Str., 1113 Sofia,
Bulgaria, has requested that FDA
withdraw approval of the following 15
NADAs and 8 ANADAs’’; and on the
same page in the table, the entry ‘‘013–
461 3–NITRO (roxarsone)/AMPROL
Plus (amprolium and ethopabate).’’ is
removed.
Dated: April 2, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014–07702 Filed 4–4–14; 8:45 am]
BILLING CODE 4160–01–P
BILLING CODE 4910–13–P
DEPARTMENT OF THE TREASURY
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Foreign Assets Control
Food and Drug Administration
31 CFR Part 560
21 CFR Parts 556 and 558
Iranian Transactions and Sanctions
Regulations
[Docket No. FDA–2014–N–0002]
Office of Foreign Assets
Control, Treasury.
ACTION: Final rule.
AGENCY:
Zoetis Inc., et al.; Withdrawal of
Approval of New Animal Drug
Applications for Combination Drug
Medicated Feeds Containing an
Arsenical Drug; Correction
AGENCY:
Food and Drug Administration,
HHS.
Notification of withdrawal of
approval; correction.
ACTION:
The Food and Drug
Administration (FDA) published a
document in the Federal Register of
February 27, 2014, concerning the
voluntary withdrawal of approval of
new animal drug applications (NADAs).
The document contained an incorrect
list of NADAs.
DATES: This correction is effective April
7, 2014.
FOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary
ehiers on DSK2VPTVN1PROD with RULES
SUMMARY:
VerDate Mar<15>2010
14:32 Apr 04, 2014
Jkt 232001
The Department of the
Treasury’s Office of Foreign Assets
Control (‘‘OFAC’’) is adopting a final
rule amending the Iranian Transactions
and Sanctions Regulations (‘‘ITSR’’) by
expanding an existing general license
that authorizes the exportation or
reexportation of food to individuals and
entities in Iran to include the broader
category of agricultural commodities.
The rule also clarifies and adds certain
definitions in OFAC regulations.
Finally, the rule adds a new general
license that authorizes the exportation
or reexportation of certain replacement
parts for certain medical devices.
DATES: Effective: April 7, 2014.
FOR FURTHER INFORMATION CONTACT:
Assistant Director for Licensing, tel.:
202/622–2480, Assistant Director for
SUMMARY:
PO 00000
Frm 00004
Fmt 4700
Sfmt 4700
Policy, tel.: 202/622–2746, Assistant
Director for Regulatory Affairs, tel.: 202/
622–4855, Assistant Director for
Sanctions Compliance and Evaluation,
tel.: 202/622–2490, Office of Foreign
Assets Control, or Chief Counsel
(Foreign Assets Control), tel.: 202/622–
2410, Office of the General Counsel,
Department of the Treasury (not toll free
numbers).
SUPPLEMENTARY INFORMATION: OFAC is
adopting a final rule amending the ITSR
by expanding an existing general license
that authorizes the exportation or
reexportation of food to individuals and
entities in Iran to include the broader
category of agricultural commodities.
Exports of certain specified items, as
well as exports to certain persons, are
excluded from the general license.
Additionally, OFAC is clarifying, for
purposes of the general licenses in ITSR
§ 560.530, that the definitions of the
terms agricultural commodities,
medicine, and medical device include,
in the case of items subject to the Export
Administration Regulations, 15 CFR
Part 730 et seq. (‘‘EAR’’), items that are
designated as EAR99 and, in the case of
items that are not subject to the EAR,
items that would be designated as
EAR99 if they were located in the
United States.
Furthermore, this rule adds a
definition of ‘‘covered person,’’ which,
with respect to the exportation or
reexportation of items subject to the
EAR, is a U.S. person or a non-U.S.
person, and for purposes of items not
subject to the EAR, is a U.S. person,
wherever located, or an entity owned or
controlled by a U.S. person and
established or maintained outside the
United States (a ‘‘U.S.-owned or
-controlled foreign entity’’). This
amendment clarifies that, for purposes
of the exportation or reexportation of
items that are not subject to the EAR,
and consistent with 31 CFR 560.556, the
general licenses set forth in § 560.530
apply to any U.S. person, wherever
located, or any U.S.-owned or
-controlled foreign entity.
Finally, OFAC is adding a new
general license that authorizes the
exportation or reexportation of
replacement parts for certain medical
devices to individuals and entities in
Iran provided that the replacement parts
are designated under the EAR as EAR99,
or would be designated as EAR99 if they
were located in the United States, and
limited to a one-for-one export or
reexport basis. This rule also updates
the definition of ‘‘basic medical
supplies’’ to exclude the word ‘‘basic’’
and make related conforming changes.
Accordingly, the ‘‘List of Basic Medical
E:\FR\FM\07APR1.SGM
07APR1
]]>Agencies
[Federal Register Volume 79, Number 66 (Monday, April 7, 2014)]
[Rules and Regulations]
[Page 18990]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07702]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 556 and 558
[Docket No. FDA-2014-N-0002]
Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug
Applications for Combination Drug Medicated Feeds Containing an
Arsenical Drug; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notification of withdrawal of approval; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) published a document in
the Federal Register of February 27, 2014, concerning the voluntary
withdrawal of approval of new animal drug applications (NADAs). The
document contained an incorrect list of NADAs.
DATES: This correction is effective April 7, 2014.
FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for
Veterinary Medicine (HFV-6), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855, 240-276-9019,
George.haibel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In FR Doc. 2014-02616, appearing on page
10974 in the Federal Register of February 27, 2014, the following
corrections are made:
On page 10974, in the third column, in the 2d line of the
``SUMMARY'' section remove ``69'' and add in its place ``68''.
On page 10975, the first bulleted text ``Huvepharma AD, 5th Floor,
3A Nikolay Haitov Str., 1113 Sofia, Bulgaria has requested that FDA
withdraw approval of the following 16 NADAs and 8 ANADAs'' is corrected
to read ``Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113 Sofia,
Bulgaria, has requested that FDA withdraw approval of the following 15
NADAs and 8 ANADAs''; and on the same page in the table, the entry
``013-461 3-NITRO (roxarsone)/AMPROL Plus (amprolium and ethopabate).''
is removed.
Dated: April 2, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-07702 Filed 4-4-14; 8:45 am]
BILLING CODE 4160-01-P
